Contact Us
Home Jazz Pharmaceuticals Announces Participation in Two Investor Conferences

News Release

Media Contact

Kristin Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc

Send Email
Ireland: +353 1 637 2141
US: 215-867-4948

Jazz Pharmaceuticals Announces Participation in Two Investor Conferences

May 15, 2015
PDF Version

DUBLIN, May 15, 2015 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentations at two upcoming investor conferences. 

  • UBS Global Healthcare Conference in New York, NY on Wednesday, May 20, 2015 at 8:00 a.m. EDT / 1:00 p.m. IST.  Bruce Cozadd, chairman and chief executive officer, will provide an overview of the company and a business and financial update.
  • Goldman Sachs 36th Annual Global Healthcare Conference in Rancho Palos Verdes, CA on Wednesday, June 10, 2015 at 10:40 a.m. PDT / 6:40 p.m. IST.  Russell Cox, executive vice president and chief operating officer, will provide an overview of the company and a business and financial update. 

A live audio webcast of each presentation may be accessed from the Investors & Media section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com.  Please connect to the website prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast.

An archive of the webcast will be available for at least one week following the presentation on the Investors & Media section of the company's website at www.jazzpharmaceuticals.com.

About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq:  JAZZ) is an international biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing meaningful products that address unmet medical needs.  The company has a diverse portfolio of products and/or product candidates with a focus in the areas of sleep and hematology/oncology.  In these areas, Jazz Pharmaceuticals markets Xyrem® (sodium oxybate) oral solution and Erwinaze® (asparaginase Erwinia chrysanthemi) in the U.S., and markets Erwinase® and Defitelio® (defibrotide) in Europe and other countries outside the U.S.  For more information, please visit www.jazzpharmaceuticals.com.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/jazz-pharmaceuticals-announces-participation-in-two-investor-conferences-300084238.html

SOURCE Jazz Pharmaceuticals plc

Jazz Pharmaceuticals Contacts: Investors, Kathee Littrell, Vice President, Investor Relations, Ireland, +353 1 634 7887, U.S., +1 650 496 2717, or Media: Laurie Hurley, Vice President, Corporate Affairs, Ireland, +353 1 634 7894, U.S., +1 650 496 2796